


CHILDREN'S VACCINE FOR 5-11 YEARS OLD



DOSE INFORMATION



The use of Pediatric Pfizer-BioNTech was authorized by Health Canada on November 19, 2021. The National Advisory Committee on Immunization (NACI) recommends a complete series (two doses) of the Pfizer-BioNTech COVID-19 vaccine. This pediatric COVID-19 vaccine is safe and effective for the 5 to 11 age group.

The new pediatric formulation of the Pfizer-BioNTech COVID-19 vaccine is 10 micrograms (mcg) compared to the 30 mcg formulation authorized for adolescents and adults 12 years of age and older.




When developing recommendations, NACI reviews clinical trial data, as well as data from real-world use of the vaccine. NACI recommends an interval of at least 8 weeks between the first and second dose since emerging evidence in adults suggests that compared to shorter intervals, longer intervals between the first and second doses result in a stronger immune response, higher vaccine effectiveness that is expected to last longer, and may be associated with a lower risk of myocarditis and/or pericarditis in adolescents and young adults.



SOURCE: [Toronto Public Health](#)



COUNCIL OF
AGENCIES SERVING
SOUTH ASIANS



SOUTH ASIAN
VACCINE
ENGAGEMENT
COLLABORATIVE